
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees is a specialty pharmaceutical company focused on developing and commercializing new therapies for infectious diseases. Its three primary products, Tafenoquine, Celgosivir, and Australian Chestnut Extracts, have shown strong potential in treating various diseases. However, the company faces risks such as limited visibility on regulatory approvals and potential dilution from future capital raises. Despite these risks, the company's strong pipeline and potential for high growth make it an attractive investment opportunity.
Bears say
60 Degrees is facing challenges in generating revenue, with a Q1 FY26 revenue miss and a high annual burn rate. While the company has raised some financing through ATM sales, its cash position is still low and it may need to continue raising equity capital to fund its operations. Additionally, the company's expansion efforts for ARAKODA may not lead to significant revenue growth in the near term, as partnerships with GoodRx and Runway Health are focused on improving affordability and patient access rather than driving sales.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares